From: Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Outcome
No palivizumab
Palivizumab
Total discounted direct costs
$ 2,970,739
$ 2,795,546
RSV-related hospitalizations
256
157
∆ Costs (palivizumab– no palivizumab)
- $ 175,193
∆ QALYs (palivizumab– no palivizumab)
45